Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDITUB: Tedizolid EBA in Pulmonary Tuberculosis
NCT05534750Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tedizolid in pulmonary tuberculosis (TB) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Early Bactericidal Activity (EBA) Day 0-2 at Day 3. Started Apr 2023; status: recruiting.
02
Drugs
tedizolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT05534750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534750.